(RS)-N-piperidin-3ylmethylbenzamide | 155542-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-N-piperidin-3ylmethylbenzamide
• 英文别名: N-(piperidin-3-ylmethyl)benzamide
• CAS: 155542-03-3
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: SIHLWNGPBLLVFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (RS)-N-piperidin-3ylmethylbenzamide 、 乙酰氯 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 12.0h， 以64%的产率得到
  参考文献：
  名称：

  Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

  摘要：

  A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.050
• 作为产物：
  描述：

  在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 19.0h， 以80%的产率得到(RS)-N-piperidin-3ylmethylbenzamide
  参考文献：
  名称：

  Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

  摘要：

  A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.050

文献信息

• Sulfonamidocarboxamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05405854A1

  公开（公告）日：1995-04-11

  Sulfonamidocarboxamides of the formula ##STR1## wherein A, M, Q, X and Y have the significance given in the description, as well as hydrates, solvates and salts thereof, which inhibit thrombin-induced blood platelet aggregation and clotting of fibrinogen in plasma, as described. The compounds of formula I can be prepared by amidination of a cyclic amino group standing for grouping X or by C(O)N(Q) amide formation.

  翻译结果如下： 公式##STR1##中的磺酰氨基甲酰胺，其中A、M、Q、X和Y的含义如描述中所述，以及它们的 hydrates（水合物）、solvates（溶剂合物）和盐，这些化合物能抑制凝血酶诱导的血小板聚集和血浆中纤维蛋白原的凝固，如所述。公式I的化合物可以通过对代表X基团的环状氨基进行酰胺化反应，或者通过C(O)N(Q)酰胺形成来制备。
• [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE
  申请人：PROSIDION LTD

  公开号：WO2011117254A1

  公开（公告）日：2011-09-29

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.

  化合物的结构式（I）或其药学上可接受的盐，可用于治疗糖尿病和肥胖。
• DPP-IV INHIBITORS
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1541143A1

  公开（公告）日：2005-06-15

  The invention relates to compounds of formula (I) wherein Z, R1-5, X, n, A1 and A2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式（I）的化合物，其中Z、R1-5、X、n、A1和A2的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及将其作为药物的生产和使用。
• Dpp-Iv Inhibitors
  申请人：Edwards Paul John

  公开号：US20080027035A1

  公开（公告）日：2008-01-31

  The invention relates to compounds of formula (I) wherein Z, R 1-5 , X, n, A 1 and A 2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及式（I）的化合物，其中Z，R1-5，X，n，A1和A2的含义如所述及权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这种化合物以及其作为药物的生产和使用。
• N-amidopiperidinyl (3/4)-oder N-amidino-1,4-oxazinyl(2)-substituierte Sulfonamide, Verfahren zur Herstellung und Verwendung als Thrombin-Inhibitoren
  申请人：F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT

  公开号：EP0559046A1

  公开（公告）日：1993-09-08

  Die neuen Sulfonamidocarboxamide der Formel worin Xeine Gruppe der Formel X¹ oder X²: TCH₂ oder O, und A, M, Q, und Y die in der Beschreibung angegebene Bedeutung haben, sowie Hydrate oder Solvate davon hemmen die durch Thrombin induzierte Plättchenaggregation und Gerinnung von Fibrinogen im Plasma. Sie werden hergestellt durch Amidinierung einer für die Gruppierung X stehenden cyclischen Aminogruppe oder durch C(O)N(Q) Amidbildung.

  新的磺酰胺类甲酰胺的化学式为 式中 X 是式 X¹ 或 X² 的基团： TCH₂ 或 O、 和 A、M、Q 和 Y 具有说明中给出的含义，其水合物或溶液可抑制凝血酶诱导的血小板聚集和血浆中纤维蛋白原的凝固。它们是通过代表基团 X 的环状氨基酰胺化或通过 C(O)N(Q) 酰胺形成制备的。